SURPASS: evaluating the next-generation of SPEAR T-cell therapy

SURPASS: Mechanism of action of ADP-A2M4CD8Подробнее

Jonathan Silk: Next Generation approaches to enhance the efficacy of SPEAR T-cellsПодробнее

SITC 2020 - Adaptimmune's SURPASS PosterПодробнее

CAR-T Cells: Poseida Therapeutics - Matt SpearПодробнее

SURPASS: ADP-A2M4CD8 T-cell receptor T-cell therapy and pembrolizumab in UCПодробнее

ADP-A2M4CD8 Mechanism of Action (Next-generation SPEAR T-cell)Подробнее

SURPASS: ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapyПодробнее

SURPASS-2: investing ADP-A2M4CD8 SPEAR T-cell therapy to treat esophageal and GEJ cancersПодробнее

Adaptimmune reports updated SURPASS data at ESMO 2021Подробнее

SPEARHEAD-2 trial design: combining SPEAR T-cells with pembrolizumabПодробнее

Adaptimmune: SPEAR T-cellsПодробнее

AACR Annual Virtual Meeting 2021 - Focus on our SURPASS and ADP-A2AFP trialsПодробнее

Developing the next generation of CAR-T cellsПодробнее

Adaptimmune Therapeutics kicks off SURPASS clinical trial to target solid tumor cancersПодробнее

Update on Adaptimmune's SURPASS Family of TrialsПодробнее

SPEAR T-cells Derived from Stem Cells Kill Cancer Targets in vitro - data from ASGCT 2020Подробнее

Adaptimmune SPEAR T-Cell Mechanism of Action VideoПодробнее

How Cancer Patients get Treated with our SPEAR T-CellsПодробнее